Top Trends Transforming the Gastroparesis Drugs Market Landscape in 2025: Development Of Innovative Gastroparesis Treatment

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Gastroparesis Drugs Industry Market Size Be by 2025?
The market size for drugs treating gastroparesis has significantly increased in the past few years. The progression is predicted to continue from $5.39 billion in 2024 to $5.73 billion in 2025, representing a compound annual growth rate (CAGR) of 6.3%. The historical growth in this market is due to factors such as the side effects of current therapies, advancements in gastrointestinal motility research, clinical necessity, patient advocacy efforts, and regulatory backing.

What's the Long-Term Growth Forecast for the Gastroparesis Drugs Market Size Through 2029?
In the following years, the gastric paresis medicine market is anticipated to witness significant expansion. Its market size will reach $7.2 billion in 2029, growing at a Compound Annual Growth Rate (CAGR) of 5.9%. This growth during the predicted period is primarily due to the surge in diabetes cases, an aging population, heightened awareness and diagnosis, higher healthcare spending, and public and private financing. The key trends for the forecasted period involve enhancements in gastroenterology, bettered diagnostic methods, innovative technology, research funding, and joint research initiatives.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

What Are the Key Growth Drivers Fueling the Gastroparesis Drugs Market Expansion?
Gastroparesis drug market expansion is anticipated due to the growing incidence of diabetes. Characterized by elevated blood sugar levels caused by insufficient insulin production or the body's inability to use insulin effectively, diabetes is a chronic health problem. Sedentary ways of living, poor dietary practices, genetic factors, urbanization, and aging populations drive the growing incidence of diabetes, exacerbated by limited healthcare access and increasing global obesity rates. Gastroparesis medications are often recommended to diabetic patients to minimize symptoms such as nausea, vomiting, and delayed stomach emptying, which are typical diabetes-related problems impacting gastrointestinal motility. The goal of these drugs is to enhance gastric activity and improve life quality for those suffering from diabetes-related gastroparesis. For example, the Office for Health Improvement & Disparities, a government department in the UK, reported in March 2024 that between March 2022 and March 2023, the number of individuals with type 1 diabetes following all eight suggested care practices rose by 22%, whereas for type 2 diabetes, it increased by 21%. Additionally, those achieving target HbA1c levels increased to 37.9%, the highest figure ever reported by the National Diabetes Audit (NDA). Consequently, the rising incidence of diabetes is fueling the expansion of the gastroparesis drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

What Are the Key Trends Driving Gastroparesis Drugs Market Growth?
The key focus of leading players in the gastroparesis drugs market is the introduction of groundbreaking drugs such as Gimoti (metoclopramide) nasal spray in order to secure a strategic advantage in the market. Gimoti (metoclopramide) nasal spray, a treatment for gastroparesis symptoms in adults, aids stomach evacuation by boosting gastrointestinal movement. The medication is absorbed directly into the circulatory system through the nasal mucosa, bypassing the gastrointestinal tract. For example, Evoke Pharma Inc., a pharmaceutical firm based in the United States, reported in April 2022 that the U.S. Food and Drug Administration (FDA) had awarded its GIMOTI (metoclopramide) nasal spray new drug product exclusivity. This exclusivity grants Evoke the sole marketing rights for the next three years, starting from the initial approval date under the Hatch-Waxman Act, shielding the product from generic counterparts.

How Is the Gastroparesis Drugs Market Segmented?
The gastroparesis drugs market covered in this report is segmented -

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs
2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes
3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types
4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration
5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:
1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements
2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

Which Companies Are Leading the Charge in Gastroparesis Drugs Market Innovation?
Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.

Which Regions Are Leading the Global Gastroparesis Drugs Market in Revenue?
North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15812

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.